26/03/2026 16:08
BOCI raised the target price for Wuxi Bio (02269) to HKD37 from HKD31 and maintained the "buy" rating.
The research house said it forecasts WuXi Bio to deliver revenue growth of 16%/15% YoY in FY26/FY27.
【你點睇？】香港IPO監管趨嚴收緊，你認為會否影響香港新股市場吸引力？你認為嚴格審批是否有助提升上市公司質素？► 立即投票
上一篇新聞︰27/03/2026 14:38 {I-bank focus}Citi lowers China OVS PPT (02669) to HKD5.2
下一篇新聞︰26/03/2026 14:43 {I-bank focus}BOCI lowers Kunlun Energy (00135) to HKD8.87
27/03/2026 16:01 {I-bank focus}Nomura lowers Sino Biopharm (01177) to HKD8.67
25/03/2026 16:02 {I-bank focus}BOCI raises Zhaojin Mining (01818) to HKD45.5
25/03/2026 14:50 {I-bank focus}BOCI raises WuXi AppTec (02359) to HKD138
24/03/2026 16:05 {I-bank focus}HSBC raises HK & China Gas (00003) to HKD6.8
24/03/2026 14:50 {I-bank focus}HSBC raises CGN Power (01816) to HKD4.1
新聞
股票N
期貨期權
權證
ETF
美股N
A股
外匯黃金
加密貨幣
基金
MPF
